Literature DB >> 17214336

Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.

Qimin He1, Tommy Fornander, Hemming Johansson, Ulla Johansson, Guo Zhu Hu, Lars-Erik Rutqvist, Sven Skog.   

Abstract

BACKGROUND: The prognostic value of the concentration of serum thymidine kinase 1 (S-TK1) with regard to recurrence in low risk breast cancer patients, 3 months after surgery was evaluated. PATIENTS AND METHODS: The concentration of S-TK1 in serum was determined in 120 breast cancer patients at the time of surgery and in 67 patients 3 months after surgery, by anti-TK1 chicken IgY antibody, using a dot-blot immuno-assay. The S-TK1 concentration was compared with the serological activity of thymidine kinase (STK) and of carbohydrate antigen (CA 15-3).
RESULTS: A statistically significant trend (unadjusted) was found for recurrence (distant or loco-regional) in patients with a higher S-TK1 concentration, as compared with patients with a lower S-TK1 concentration. A multivariate analysis gave the same results. The hazard rate ratio for developing distant and/or loco-regional recurrence in patients with a higher S-TK1 concentration was about six to seven times higher than in patients with a lower S-TK1 concentration.
CONCLUSION: Our results indicate that the S-TK1 concentration is higher in patients developing distant and/or loco-regional recurrence 3 months post-surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214336

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

1.  High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.

Authors:  Yan Xu; Qun-Li Shi; Henghui Ma; Hangbo Zhou; Zhenfeng Lu; Bo Yu; Xiaojun Zhou; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Tumour Biol       Date:  2011-12-06

2.  Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.

Authors:  Yan Chen; Mingang Ying; YanSong Chen; Minhua Hu; Yingying Lin; Dedong Chen; Xiaoli Li; Ming Zhang; Xia Yun; Ji Zhou; Ellen He; Sven Skog
Journal:  Int J Clin Oncol       Date:  2010-04-01       Impact factor: 3.402

3.  Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer.

Authors:  Yongping Liu; Yang Ling; Qiufeng Qi; Yexin Tang; Jianzhong Xu; Zhou Tong; Guifeng Sheng; Quanliang Yang; Yaodong Pan
Journal:  Exp Ther Med       Date:  2011-08-17       Impact factor: 2.447

4.  Serum thymidine kinase 1 is a reliable maker for the assessment of the risk of developing malignancy: A case report.

Authors:  Zhiheng Chen; Hong Guan; Hong Yuan; Xia Cao; Yingxin Liu; J I Zhou; Ellen He; Sven Skog
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

5.  Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study.

Authors:  Zilin Qin; Jibing Chen; Jianying Zeng; Lizhi Niu; Silun Xie; Xiaohua Wang; Yingqing Liang; Zhenyi Wu; Mingjie Zhang
Journal:  Cancer Biol Ther       Date:  2017-03-29       Impact factor: 4.742

6.  The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells.

Authors:  Pengcheng Luo; Naining Wang; Ellen He; Staffan Eriksson; Ji Zhou; Guozhu Hu; Jie Zhang; Sven Skog
Journal:  Pathol Oncol Res       Date:  2009-12-03       Impact factor: 3.201

7.  Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.

Authors:  Wei Xu; Xin Cao; Kou-Rong Miao; Chun Qiao; Yu-Jie Wu; Qiong Liu; Lei Fan; Jian-Yong Li
Journal:  Int J Hematol       Date:  2009-07-24       Impact factor: 2.490

8.  Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.

Authors:  Mohamed Elfagieh; Fathi Abdalla; Asma Gliwan; Jamela Boder; Wafa Nichols; Abdelbaset Buhmeida
Journal:  Tumour Biol       Date:  2012-09-05

Review 9.  The proliferation marker thymidine kinase 1 in clinical use.

Authors:  Ji Zhou; Ellen He; Sven Skog
Journal:  Mol Clin Oncol       Date:  2012-09-04

10.  Serological thymidine kinase 1 is a biomarker for early detection of tumours--a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay.

Authors:  Zhi Heng Chen; Shou Qing Huang; Yande Wang; Ai Zhen Yang; Jian Wen; Xiao Hong Xu; Yan Chen; Qu Bo Chen; Ying Hong Wang; Ellen He; Ji Zhou; Sven Skog
Journal:  Sensors (Basel)       Date:  2011-11-28       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.